AbClon Inc is a Korea-based company principally engaged in the development, manufacture and distribution of antibody drug. The Company developed a bio synergy antibody, a therapeutic antibody for a new mechanism that is different from conventional therapeutic agents, and is based on the YPLUS and AffiMab platforms. The company's products include AC101, AC103, AC104, AC106, AC203, AM201, AM101, AM102 and AM103. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	₩28,000.00	+2.56%	148,989
06/08/26	₩27,300.00	+4.20%	226,005
05/08/26	₩26,200.00	-1.13%	184,558
04/08/26	₩26,500.00	+20.73%	499,801
03/08/26	₩21,950.00	+11.42%	146,070

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 07/08/2026			5-day change	1st Jan Change
28,000.00 ^KRW	+2.56%		+62.04%	-34.12%

06-08	Alligator partner Henlius doses first patients in HLX22 study	FW
05-22	Alligator Bioscience comments on Henlius update for HLX22	FW

Market Cap	559B 396M 343M 320M 294M 552M 37.72B 561M 3.76B 1.47B 18.91B 1.49B 1.46B 62.51B	P/E 2024	-14.5x	P/E 2025	-43.5x
Enterprise Value	521B 369M 320M 298M 274M 515M 35.16B 523M 3.5B 1.37B 17.62B 1.39B 1.36B 58.26B	EV / Sales 2024	103x	EV / Sales 2025	164x
Free-Float	80.08%	Yield 2024 *	-	Yield 2025	-

06-08	Alligator partner Henlius doses first patients in HLX22 study	FW
05-22	Alligator Bioscience comments on Henlius update for HLX22	FW
04-23	Alligator partner Henlius presents preclinical data for HLX49	FW
04-23	Alligator Bioscience Announces Preclinical Data Presentation of Hlx49 Antibody?Drug Conjugate	CI
04-07	Abclon wins 396 million won order	RE
03-09	AbClon wins 778 million won order	RE
03-02	Alligator Bioscience: First Patient Dosed in Phase 2/3 Study with HLX22 in China	FW
30/09/25	AbClon Inc. announced that it expects to receive KRW 35.999952065 billion in funding from Paratus Investment Inc., Dongyu Investment Co., Ltd, Winvest Venture Capital and other investors.	CI
27/08/25	Abclon wins 309 million won order	RE
20/05/25	Abclon Wins 354 Million Won Order	RE
19/05/25	AbClon Inc To Issue 1.4 Million Common Shares	RE
18/05/25	AbClon Inc. announced that it has received KRW 12.2122 billion in funding from Chong Kun Dang Pharmaceutical Corp.	CI
15/05/25	Abclon Wins 307 Million Won Order	RE

06-08	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
05-22	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
04-23	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
03-02	Alligator Bioscience comments on Henlius dosing first patient in Phase 2/3 breast cancer study of HLX22	AQ
04/12/24	Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial	AQ

AbClon Inc. Share Price

Stocks

A174900

KR7174900001

Pharmaceuticals

Valuation: AbClon Inc.

Chart: AbClon Inc.

Latest news : AbClon Inc.

Press Releases: AbClon Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AbClon Inc.

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+2.56%
1 week	+62.04%
Current month	+42.13%
1 month	+9.16%
3 months	-39.20%
6 months	-52.86%
Current year	-34.12%

1 week	19,220	28,650
1 month	16,250	28,650
Current year	16,250	95,800
1 year	9,770	95,800
3 years	6,810	95,800
5 years	6,810	95,800
10 years	6,810	95,800

Manager	Title	Age	Since
Jong-Seo Lee CEO	Chief Executive Officer	63	24/06/2010
Doo-Hun Kim DFI	Director of Finance/CFO	59	27/03/2024
Jong-Hoon Kim CTO	Chief Tech/Sci/R&D Officer	57	28/03/2023

Director	Title	Age	Since
Jong-Seo Lee BRD	Director/Board Member	63	-
Jung-Ho Kim BRD	Director/Board Member	62	28/03/2021
Jong-Hoon Kim BRD	Director/Board Member	57	28/03/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCLON INC.	+2.56%	+62.04%	+157.59%	+55.64%	383M
REGENERON PHARMACEUTICALS, INC.	+1.24%	+2.20%	+39.22%	+0.60%	77.1B
UCB	-0.84%	+0.09%	+20.92%	+179.15%	49.43B
SAMSUNG BIOLOGICS CO.,LTD.	+2.77%	+1.90%	-1.84%	+27.14%	49.27B
CSL LIMITED	-0.13%	+3.33%	-50.97%	-50.14%	44.59B
BIOGEN INC.	-0.19%	+1.27%	+60.88%	-24.22%	30.48B
INCYTE CORPORATION	+1.19%	+0.46%	+53.54%	+84.97%	24B
MODERNA, INC.	+7.06%	+4.68%	+115.65%	-43.30%	21.5B
INNOVENT BIOLOGICS, INC.	+4.29%	+7.66%	-3.26%	+189.18%	20.18B
SWEDISH ORPHAN BIOVITRUM AB	+1.66%	-3.70%	+65.40%	+123.91%	16.29B
Average	+1.97%	+3.46%	+45.71%	+54.29%	33.32B
Weighted average by Cap.	+1.43%	+2.61%	+25.15%	+42.71%

	2024	2025
Net sales	2.34B 1.66M 1.44M 1.34M 1.23M 2.31M 158M 2.35M 15.73M 6.18M 79.19M 6.23M 6.1M 262M	4.71B 3.34M 2.89M 2.7M 2.48M 4.66M 318M 4.74M 31.7M 12.44M 160M 12.56M 12.28M 527M
Net income	-16.3B -11.57M -10M -9.34M -8.57M -16.12M -1.1B -16.38M -110M -43.02M -552M -43.43M -42.48M -1.82B	-17.91B -12.7M -10.99M -10.26M -9.41M -17.71M -1.21B -17.99M -120M -47.26M -606M -47.71M -46.67M -2B
Net Debt	-4.61B -3.27M -2.83M -2.64M -2.42M -4.56M -311M -4.63M -31.01M -12.17M -156M -12.29M -12.02M -516M	-37.93B -26.91M -23.28M -21.74M -19.94M -37.5M -2.56B -38.1M -255M -100M -1.28B -101M -98.83M -4.24B